Cebranopadol

DRUG4 trials

Sponsors

Tris Pharma, Inc., Adneuris Therapeutics, Inc.

Conditions

Acute PainChronic PainNeoplasmsOpioid Use DisorderOpioid Withdrawal (Disorder)Pain

Phase 2

A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain

RecruitingNCT07874620

Adneuris Therapeutics, Inc.Chronic Pain, Opioid Use Disorder, Opioid Withdrawal (Disorder) +1

Start: 2026-10-01End: 2027-06-01Target: 45Updated: 2026-10-23

Phase 3

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer

TerminatedNCT01964378

Tris Pharma, Inc.Chronic Pain, Neoplasms, Pain

Start: 2013-10-29End: 2015-10-16Updated: 2021-07-15

CORAL XT - Open-label Extension Trial of the CORAL Trial

CompletedNCT02031432

Tris Pharma, Inc.Chronic Pain, Neoplasms, Pain

Start: 2013-12-18End: 2016-05-03Updated: 2021-07-15

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

CompletedNCT06423703

Tris Pharma, Inc.Acute Pain

Start: 2024-07-18End: 2025-01-31Updated: 2026-01-26